Eli Lilly conducts an autopsy of an Alzheimer’s megaflop
For four years Eli Lilly $LLY committed one of the biggest clinical efforts in the company’s history to proving that it could get solanezumab right on Alzheimer’s. Having navigated through multiple trial failures already, investigators were convinced that if they took what they had learned, changed the patient population, sticking to only patients with a mild form of the disease while using better diagnostics — even changing the endpoints in the lead up to the final read out — they could make a case that this drug could make a significant improvement for patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.